|
1
|
Byrd JC, Furman RR, Coutre SE, Flinn IW,
Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et
al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic
leukemia. N Engl J Med. 369:32–42. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Singh SP, Pillai SY, de Bruijn MJW,
Stadhouders R, Corneth OBJ, van den Ham HJ, Muggen A, van IJcken W,
Slinger E, Kuil A, et al: Cell lines generated from a chronic
lymphocytic leukemia mouse model exhibit constitutive Btk and Akt
signaling. Oncotarget. 8:71981–71995. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gribben JG and O'Brien S: Update on
therapy of chronic lymphocytic leukemia. J Clin Oncol. 29:544–550.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Seda V and Mraz M: B-cell receptor
signalling and its crosstalk with other pathways in normal and
malignant cells. Eur J Haematol. 94:193–205. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu Y, Dong Y, Jiang QL, Zhang B and Hu
AM: Bruton's tyrosine kinase: Potential target in human multiple
myeloma. Leuk Lymphoma. 55:177–181. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yaktapour N, Meiss F, Mastroianni J, Zenz
T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B,
et al: BRAF inhibitor-associated ERK activation drives development
of chronic lymphocytic leukemia. J Clin Invest. 124:5074–5084.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Rushworth SA, Bowles KM, Barrera LN,
Murray MY, Zaitseva L and MacEwan DJ: BTK inhibitor ibrutinib is
cytotoxic to myeloma and potently enhances bortezomib and
lenalidomide activities through NF-κB. Cell Signal. 25:106–112.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barrientos J and Rai K: Ibrutinib: A novel
Bruton's tyrosine kinase inhibitor with outstanding responses in
patients with chronic lymphocytic leukemia. Leuk Lymphoma.
54:1817–1820. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chang HM, Martinez NJ, Thornton JE, Hagan
JP, Nguyen KD and Gregory RI: Trim71 cooperates with microRNAs to
repress Cdkn1a expression and promote embryonic stem cell
proliferation. Nat Commun. 3(923)2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kovaleva V, Mora R, Park YJ, Plass C,
Chiramel AI, Bartenschlager R, Döhner H, Stilgenbauer S, Pscherer
A, Lichter P and Seiffert M: miRNA-130a targets ATG2B and DICER1 to
inhibit autophagy and trigger killing of chronic lymphocytic
leukemia cells. Cancer Res. 72:1763–1772. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Audrito V, Vaisitti T, Rossi D, Gottardi
D, D'Arena G, Laurenti L, Gaidano G, Malavasi F and Deaglio S:
Nicotinamide blocks proliferation and induces apoptosis of chronic
lymphocytic leukemia cells through activation of the
p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res.
71:4473–4483. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gao Y, Yin Y, Xing X, Zhao Z, Lu Y, Sun Y,
Zhuang Z, Wang M, Ji W and He Y: Arsenic-induced anti-angiogenesis
via miR-425-5p-regulated CCM3. Toxicol Lett. 254:22–31.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu L, Zhao Z, Zhou W, Fan X, Zhan Q and
Song Y: Enhanced expression of miR-425 promotes esophageal squamous
cell carcinoma tumorigenesis by targeting SMAD2. J Genet Genomics.
42:601–611. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Nakagawa R, Muroyama R, Koike K, Saeki C,
Ito S, Morimoto S, Goto K, Matsubara Y, Kato N and Zeniya M:
Decreased mir-425 induced inflammatory cytokine production via
N-RAS upregulation in CD4+ T cells of primary biliar cholangitis. J
Hepatol. 64 (Suppl):S643–S644. 2016.
|
|
17
|
He B, Li T, Guan L, Liu FE, Chen XM, Zhao
J, Lin S, Liu ZZ and Zhang HQ: CTNNA3 is a tumor suppressor in
hepatocellular carcinomas and is inhibited by miR-425. Oncotarget.
7:8078–8089. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Peng WZ, Ma R, Wang F, Yu J and Liu ZB:
Role of miR-191/425 cluster in tumorigenesis and diagnosis of
gastric cancer. Int J Mol Sci. 15:4031–4048. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fu Y, Xu X, Xue J, Duan W and Yi Z:
Deregulated lncRNAs in B cells from patients with active
tuberculosis. PLoS One. 12(e0170712)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cai BL, Xu XF, Fu SM, Shen LL, Zhang J,
Guan SM and Wu JZ: Nuclear translocation of MRP1 contributes to
multidrug resistance of mucoepidermoid carcinoma. Oral Oncol.
47:1134–1140. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cai BL, Li Y, Shen LL, Zhao JL, Liu Y, Wu
JZ, Liu YP and Yu B: Nuclear multidrug resistance-related protein 1
is highly associated with better prognosis of human mucoepidermoid
carcinoma through the suppression of cell proliferation, migration
and invasion. PLoS One. 11(e0148223)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bottoni A, Rizzotto L, Lai TH, Liu C,
Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, et
al: Targeting BTK through microRNA in chronic lymphocytic leukemia.
Blood. 128:3101–3112. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kaderi MA, Kanduri M, Buhl AM, Sevov M,
Cahill N, Gunnarsson R, Jansson M, Smedby KE, Hjalgrim H, Jurlander
J, et al: LPL is the strongest prognostic factor in a comparative
analysis of RNA-based markers in early chronic lymphocytic
leukemia. Haematologica. 96:1153–1160. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ma J, Liu J, Wang Z, Gu X, Fan Y, Zhang W,
Xu L, Zhang J and Cai D: NF-kappaB-dependent microRNA-425
upregulation promotes gastric cancer cell growth by targeting PTEN
upon IL-1β induction. Mol Cancer. 13(40)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Feng F, Song T, Zhang T, Cui Y, Zhang G
and Xiong Q: MiR-425-5p promotes invasion and metastasis of
hepatocellular carcinoma cells through SCAI-mediated dysregulation
of multiple signaling pathways. Oncotarget. 8:31745–31757.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Di Leva G, Piovan C, Gasparini P, Ngankeu
A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder
H, et al: Estrogen mediated-activation of miR-191/425 cluster
modulates tumorigenicity of breast cancer cells depending on
estrogen receptor status. PLoS Genet. 9(e1003311)2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen FF, Xiong Y, Peng Y, Gao Y, Qin J,
Chu GY, Pang WJ and Yang GS: miR-425-5p inhibits differentiation
and proliferation in porcine intramuscular preadipocytes. Int J Mol
Sci. 18(pii: E2101)2017.PubMed/NCBI View Article : Google Scholar
|
